Remove Heart Failure Remove Innovation Remove Preserved Ejection Fraction
article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano , President & Chief Executive Officer of Tenax Therapeutics. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Mouse study finds increasing cardiac ketones may help treat heart failure

Medical Xpress - Cardiology

Increasing ketone supply to the heart in mice with heart failure with preserved ejection fraction (HFpEF) allowed their hearts to utilize more ketones and produce more energy, according to preliminary research presented today at the American Heart Association's Basic Cardiovascular Sciences Scientific Sessions 2024.

article thumbnail

Developing a contemporary community clinic for patients with heart failure with preserved ejection fraction within the current National Health Service model

Open Heart

Introduction The diagnostic and therapeutic arsenal for heart failure with preserved ejection (HFpEF) has expanded. We; therefore, evaluated the efficacy of an existing dedicated HFpEF clinic to find innovative ways to design a more comprehensive model tailored to the modern era of HFpEF.

article thumbnail

American College of Cardiology Sets Full Range of Education Sessions and Meetings ACC Scientific Session, ACC.24

DAIC

Featured topics will include in-depth sessions covering non-statin lipid lowering therapies, heart failure with preserved ejection fraction, viability, imaging modalities for the assessment of coronary artery disease, and antiplatelet therapy after coronary stenting. 24 news here.

Education 105
article thumbnail

Basic Science of Cardiac Contractility Modulation Therapy: Molecular and Electrophysiological Mechanisms

HeartRhythm

In heart failure with reduced ejection fraction and heart failure with preserved ejection fraction, profound cellular and molecular changes have recently been documented in the failing myocardium.These changes include altered calcium handling and metabolic efficiency of the cardiac myocyte, reactivation of the fetal gene program, changes in the electrophysiological (..)

article thumbnail

Corvia atrial shunt system: Mean LA pressure reduction device in HFpEF

Dr. S. Venkatesan MD

May be, it will come soon in the innovative lanes of cardiology. Shah, author of Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial. Probably in the thin membranous area. Interview with Sanjiv J.

article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With Preserved Ejection Fraction, (..)